SUBSCRIBE: Print / eNewsletter
Cancer Network presents exclusive coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Check out some of our topic specific ASCO coverage:
Pembrolizumab Offers Extended Survival in Advanced Melanoma Patients
Treatment with the anti–PD-1 antibody pembrolizumab yielded good long-term survival outcomes in a phase Ib trial of patients with advanced melanoma.
Left-Side Primary Tumors Predict Longer Survival in Metastatic CRC
The physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer, according to an analysis to be presented at ASCO.
Thyroid Cancer Diagnosis Affects Employment, Income
Survivors of thyroid cancer had a higher risk of unemployment at 2 years post-diagnosis and decreased income at both 2 and 4 years, according to the results of a study.
FNA Analysis Could Help Predict Thyroid Cancer Recurrence Risk
Use of transcriptional data taken from the FNA of thyroid nodules could help in predicting recurrence post surgery in certain thyroid cancer patients.
ASCO Poster Sessions: Breast Cancer in Elderly Women
As physicians, we strive to do no harm, and there is a narrow therapeutic window when treating elderly patients with cancer.
TDM-1 Better Than Trastuzumab in HER2-, HR-Positive Breast Cancer
Neoadjuvant TDM-1 was shown to be effective in treating HER2-positive, HR-positive breast cancer compared with trastuzumab, with or without endocrine therapy.
Patient Beliefs Tied to Suboptimal Adherence to CML Medications
Beliefs regarding medication for chronic myeloid leukemia (CML) are strongly associated with suboptimal treatment adherence, according to a new study.
Neoadjuvant Pertuzumab Adds Benefit in HER2-Positive Breast Cancer
The addition of pertuzumab to trastuzumab and docetaxel offers significant improvement over other options in patients with HER2-positive breast cancer.
Alectinib Promising in ALK-Positive Advanced NSCLC
Alectinib yielded good response rates and was very well tolerated in a phase II trial of patients with advanced, ALK-positive non–small-cell lung cancer.
No Difference in Efficacy for Three Bisphosphonates in Breast Cancer
A large randomized trial showed that three different bisphosphonates have similar efficacy in early-stage breast cancer.